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Abstract  Severe  sepsis  and  septic  shock  represent  a  major  healthcare  challenge.  Much  of  the
improvement  in  mortality  associated  with  septic  shock  is  related  to  early  recognition  combined
with timely  ﬂuid  resuscitation  and  adequate  antibiotics  administration.  The  main  goals  of  sep-
tic shock  resuscitation  include  intravascular  replenishment,  maintenance  of  adequate  perfusion
pressure  and  oxygen  delivery  to  tissues.  To  achieve  those  goals,  ﬂuid  responsiveness  evalua-
tion and  complementary  interventions  --  i.e.  vasopressors,  inotropes  and  blood  transfusion  --
may be  necessary.  This  article  is  a  literature  review  of  the  available  evidence  on  the  initial
hemodynamic  support  of  the  septic  shock  patients  presenting  to  the  emergency  room  or  to  the
intensive  care  unit  and  the  main  interventions  available  to  reach  those  targets,  focusing  on
ﬂuid and  vasopressor  therapy,  blood  transfusion  and  inotrope  administration.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
PALAVRAS-CHAVE
Choque  séptico;
Hemodinâmica;
Reposic¸ão  volêmica;
Fluidoterapia;
Agentes
Conceitos  atuais  sobre  suporte  hemodinâmico  e  terapia  em  choque  séptico
Resumo  A  sepse  grave  e  o  choque  séptico  são  um  grande  desaﬁo  para  a  assistência  médica.
Grande parte  da  melhora  na  taxa  de  mortalidade  associada  ao  choque  séptico  está  rela-
cionada ao  reconhecimento  precoce  em  combinac¸ão  com  a  reposic¸ão  volêmica  oportuna  e
a administrac¸ão  adequada  de  antibióticos.  Os  principais  objetivos  da  reanimac¸ão  do  choquevasoconstritores séptico incluem  reposic¸ão  intravascular,  manutenc¸ão  adequada  da  pressão  de  perfusão  e  fornec-
imento de  oxigênio  para  os  tecidos.  Para  atingir  esses  objetivos,  a  avaliac¸ão  da  responsividade
do volume  e  das  intervenc¸ões  complementares  (vasopressores,  inotrópicos  e  transfusão  de
sangue) pode  ser  necessária.  Este  artigo  é  uma  revisão  da  literatura  para  identiﬁcar  as  evidên-
cias disponíveis  do  suporte  hemodinâmico  inicial  aos  pacientes  com  choque  séptico  admitidos
em sala  de  emergência  ou  unidade  de  terapia  intensiva  e  as  principais  intervenc¸ões  disponíveis
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para  atingir  essas  metas,  com  foco  em  terapia  com  reposic¸ão  de  líquidos  e  vasopressores,
transfusão de  sangue  e  administrac¸ão  de  inotrópicos.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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epsis,  a  systemic  inﬂammatory  response  associated  to  an
nfection,  is  a  common  disease  with  an  estimated  incidence
f  300  cases  per  100,000  people  and  with  an  incidence
ncrease  of  13%  per  year.1,2 Approximately  half  of  septic
atients  will  develop  the  most  severe  spectrum  of  this  dis-
ase,  i.e.  severe  sepsis  and  septic  shock.3
Septic  shock  carries  an  average  in-hospital  mortality  rate
round  20%  and  a  90  day  mortality  rate  between  20%  and
0%.4--10 In  Brazil,  the  28  day  mortality  rate  achieves  around
0%  with  an  incidence  density  of  thirty  cases  per  thousand
atient-days.11
Septic  shock  is  also  associated  with  high  burden  of  mor-
idity  and  costs.  The  average  cost  per  patient  is  US$  22,100,
hich  accounts  for  an  annual  expenditure  of  approximately
eventeen  billion  dollars  in  the  United  States  alone.1 Addi-
ionally,  the  quality  of  life  and  cognitive  function  of  sepsis
urvivors  may  be  permanently  compromised.12--14 Key  inter-
entions  to  improve  outcomes  in  this  population  of  critically
ll  patients  include  early  recognition  and  early  onset  of
dequate  therapy,  mainly  broad-spectrum  antibiotics  and
uids.15
The  initial  attempts  to  optimize  hemodynamics  in  criti-
al  care  patients  were  deemed  ineffective,  increasing  the
isk  of  death.16,17 During  the  past  decade,  the  early  goal-
irected  therapy  principle  encompassing  early  series  of
rotocolized  interventions,  i.e.  antibiotics,  ﬂuids,  vaso-
ressors,  inotropes,  red  blood  transfusion,  etc.,  showed
igniﬁcant  reduction  of  mortality  rate.18 This  strategy  has
een  recommended  by  specialty  societies  in  their  guidelines
or  severe  sepsis  and  septic  shock  treatment  and  has  been
mplemented  in  emergency  departments  and  intensive  care
nits  in  a  global  scale.15
According  to  these  guidelines,  septic  patients  presenting
ith  signs  of  persistent  hypotension  (i.e.  mean  arterial
lood  pressure  <65  mmHg  despite  initial  adequate  ﬂuid
esuscitation)  or  tissue  hypoperfusion  (i.e.  arterial  lac-
ate  concentration  equal  to  or  higher  than  4.0  mmol/L)
ave  a  high  risk  of  death  and  therefore  must  be  promptly
esuscitated.15
Nevertheless,  there  is  increasing  evidence  coming
rom  new  randomized  clinical  trials  challenging  the
fﬁcacy  of  the  early  goal-directed  therapy  for  septic
atients.8,9 Therefore,  we  propose  a  narrative  review
f  the  literature  supporting  the  management  of  the
arly  stages  of  septic  shock,  with  special  attention
o  hemodynamics  evaluation  and  evidence-based  inter-
entions,  taking  into  account  the  recently  published
ata.
t
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tbjective
ur  objective  was  to  perform  a  narrative  review  of  the
vailable  evidence  on  hemodynamic  support  for  septic  shock
atients  and  provide  an  overview  of  the  key  available  inter-
entions  for  resuscitation,  e.g.  ﬂuid  therapy,  vasopressors,
notropes  and  red  blood  transfusion.
ethods
e  performed  a  systematic  search  in  MEDLINE/Pubmed,
mbase/OVID,  LILACS/Bireme  and  Cochrane  Library  up  to
ctober  2014  using  the  Medical  Subject  Headings  (MeSH)
erms  ‘‘sepsis’’,  ‘‘severe  sepsis’’  AND/OR  ‘‘septic  shock’’
ombined  with  ‘‘central  venous  pressure’’,  ‘‘lactate’’,
‘lactate  clearance’’,  ‘‘mean  arterial  pressure’’,
‘blood  pressure’’,  ‘‘vasopressors’’,  ‘‘norepinephrine’’,
‘epinephrine’’,  ‘‘vasopressin’’,  ‘‘central  venous  oxy-
en  saturation’’,  ‘‘blood  transfusion’’,  ‘‘transfusion’’,
‘dobutamine’’,  ‘‘ﬂuid  responsiveness’’.
We  have  limited  our  search  to  articles  written  in  English,
uman  subjects  and  clinical  trials.  We  also  reviewed  the
urrent  Surviving  Sepsis  Campaign  Guidelines  for  the  Treat-
ent  of  Severe  Sepsis  and  Septic  Shock  and  their  key  related
rticles.15 Additional  studies  were  added  at  authors’  discre-
ion.  One  hundred  and  seventy-nine  articles  were  retrieved
rom  this  search  and  further  ﬁltered  for  quality  and  origi-
ality  before  being  included  in  this  review.
emodynamic goals
he  imbalance  between  oxygen  consumption  and  oxygen
elivery  is  the  main  determinant  of  the  development  and
rogression  of  organ  dysfunction  in  septic  shock  patients.
herefore,  the  aim  of  the  hemodynamic  interventions  com-
only  applied  to  these  patients  is  to  increase  oxygen
elivery  to  match  oxygen  demand  (Fig.  1).
The  currently  recommended  hemodynamic  targets  to  be
chieved  during  the  initial  six-hour  of  resuscitation  include
 central  venous  pressure  (CVP)  between  8  and  12  mmHg
n  spontaneously  breathing  patients  or  between  12  and
5  mmHg  in  mechanically  ventilated  patients  or  in  those  with
educed  ventricular  compliance,  a  mean  arterial  blood  pres-
ure  (MAP)  ≥65  mmHg,  a  central  venous  (ScvO2)  or  mixed
enous  (SvO2)  oxygen  saturations  ≥70%  and  65%  respec-
ively,  a  lactate  clearance  ≥10%  and  an  urinary  output
0.5  mL/kg/h  (Fig.  2).15
Recently,  two  large  randomized  clinical  trials  confronted
he  efﬁcacy  of  early  goal-directed  therapy  in  septic  shock.8,9
Hemodynamic  support  in  septic  shock  
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Figure  1  Relationship  between  oxygen  delivery,  oxygen  con-
sumption,  oxygen  extraction  rate  and  lactate  in  healthy  (1)  and
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Acritically  ill  (2)  patients  with  shock.  DO2,  oxygen  delivery;  VO2,
oxygen consumption;  O2ER,  oxygen  extraction  rate.
The  ﬁrst  one,  the  ProCESS  trial,  assessed  three  different
resuscitation  strategies  for  septic  shock  patients.8 This  study
showed  no  60  day  mortality  difference  when  usual  care
(i.e.  no  pre-speciﬁed  protocol),  protocol-based  early  goal
direct  therapy  (i.e.  central  venous  line  insertion  with  SvcO2
and  CVP  guidance)  and  protocol-based  standard  therapy
(i.e.  without  central  venous  line  placement  nor  ScvO2  and
CVP  guidance)  were  compared.8 In  the  second  study,  the
ARISE  trial,  septic  shock  patients  were  randomized  for  early
goal-directed  therapy  or  usual  care  (at  clinical  team  dis-
cretion  and  without  ScvO2  measurement  during  the  ﬁrst  six
hours  of  resuscitation).9 There  was  no  difference  in  the  pri-
mary  outcome,  which  was  mortality  on  the  90th  day  after
randomization.  Additionally,  the  early  goal-directed  ther-
apy  group  received  signiﬁcantly  more  ﬂuids,  vasopressors,
inotropes  and  red  blood  cell  transfusion.9 A  third  ongoing
trial  (ProMISe),  addressing  the  efﬁcacy  of  the  early  goal
directed  in  septic  shock  completed  enrollment  of  patients
(Controlled-trials.com:  ISRCTN36307479).
Considering  these  results,  it  can  be  assumed  that
early  recognition  and  treatment  provision  for  septic  shock
patients  should  be  the  main  concern  and  priority  for
clinicians  at  the  bedside  rather  than  strictly  follow  a  goal-
directed  protocol.  In  the  next  sections,  we  will  discuss  the
main  hemodynamic  interventions  individually.Central  venous  pressure  and  ﬂuid  responsiveness
Central  venous  pressure  is  the  pressure  recorded  from  the
right  atrium  or  at  the  superior  vena  cava  by  the  insertion
A
m
(
t
Table  1  Main  methods  available  to  address  ﬂuid  responsiveness  i
Methods  Cutoff  values  Mechanical  ventilatio
CVP4,5 <8--12  mmHg  No/yes  
PP6 >13%  Yes  
IVC distensibility7 >18%  Yes  
PLR8 CI  >10%  No  
CVP, central venous pressure; PP, arterial pulse pressure variation; IV
RV, right ventricle; N/A, not available; US, ultrasonography.397
f  a  central  venous  catheter.19 The  CVP  is  determined
y  a complex  interaction  between  cardiac  function  and
enous  return,  and  represents  a  static  indicator  of  cardiac
reload.19 Central  venous  pressure  is  not  an  accurate  predic-
or  of  ﬂuid  responsiveness  in  critically  ill  patients.20 Never-
heless,  it  has  been  used  widely  with  this  purpose  (Table  1).20
The  evaluation  of  arterial  pulse  pressure  variation  due  to
eart--lung  interactions  represents  a  dynamic  and  accurate
redictor  of  ﬂuid  responsiveness  that  can  be  used  to  dis-
riminate  between  patients  who  will  and  will  not  increase
ardiac  output  after  a ﬂuid  challenge  (Table  1).21 However,
n  arterial  line  placement,  absence  of  patient’s  respiratory
fforts,  usually  obtained  by  deep  sedation  and  neuromus-
ular  blockers,  volume  controlled  mechanical  ventilation
ith  tidal  volume  between  8  and  12  mL/kg,  positive  end
xpiratory  pressure  lower  than  10  cm  H2O  and  a  regular
ardiac  rhythm  are  required  for  pulse  pressure  variation
ssessment.21 Other  available  methods  to  address  ﬂuid
esponsiveness  in  critically  ill  patients  include  bedside  ultra-
ound  analysis  of  the  inferior  vena  cava22 and  the  passive  leg
aising  test  (Table  1).23
The  distensibility  index  of  the  inferior  vena  cava  is  cal-
ulated  from  the  M  mode  of  the  thoracic  echocardiogram
t  the  subcostal  window  as  follows:  maximum  inferior  vena
ava  diameter  minus  minimum  inferior  vena  cava  diame-
er  divided  by  maximum  inferior  vena  cava  diameter.22 An
nferior  vena  cava  distensibility  index  above  18%  is  highly
orrelated  with  a 15%  cardiac  index  increase  after  a  ﬂuid
hallenge.22 Inferior  vena  cava  analysis  also  requires  deeply
edated,  mechanically  ventilated  patients  with  mild  or  no
espiratory  effort  and  a  regular  cardiac  rhythm  to  be  accu-
ately  performed.22
The  passive  leg-raising  test  is  a  sequential  maneuver  in
hich  the  patient  is  initially  in  a  semi-recumbent  position
nd  afterwards  both  legs  are  elevated  45  degrees  in  relation
o  the  ground  with  the  patient  in  the  supine  position  for  one
inute.23 This  test  simulates  a  ﬂuid  challenge  in  a  way  that
lood  from  the  inferior  limbs  is  mobilized  to  the  heart.  An
ncrease  greater  than  10%  in  measured  blood  ﬂow  is  highly
redictive  of  ﬂuid  responsiveness.23 This  maneuver  can  be
erformed  in  spontaneously  breathing  patients  and  in  the
resence  of  cardiac  arrhythmia.23
rterial  blood  pressure mean  arterial  pressure  ≥65  mmHg  has  been  recom-
ended  during  the  initial  resuscitation  of  septic  shock
Fig.  2).15 However,  few  studies  are  available  to  support
his  recommendation.6,24--28 This  lack  of  available  data  is
n  critically  ill  patients.
n?  Arrhythmia?  Limitations
Yes  Limited  in  critically  ill  patients
No  RV  dysfunction
No  US  training
Yes  N/A
C, inferior vena cava; PLR, passive leg raising; CI, cardiac index;
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Oxygen  ± ETI and MV
Central venous and arterial
catheterization
<8
8-12 mmHg*
MAP
LacCI
No Yes
AND/OR
Dobutamine
Vasoactive agents‡
Consider albumin 4%-5%
Crystalloids (30 mL/kg)
Goals
achieved?
Reevaluation periodically
Transfusion RBC until HCT ≥30%
ScvO2
mmHg
<65 mmHg
<70%
CVP
Access F-R
Sedation ± NMB
(if intubated)
ΔPP; ECHO/dIVC; PLR; other
≥65 mmHg
≥10% ≥70%
Figure  2  Suggested  goal-directed  therapy  algorithm  for  septic  shock  resuscitation.  It  is  important  to  note  that  only  hemodynamic
goals are  depicted  in  this  algorithm.  The  other  components  of  sepsis  bundles  (e.g.  antibiotic  therapy,  source  control,  etc.)  are
activated concomitantly.  ETI,  endotracheal  intubation;  MV,  mechanical  ventilation;  NBM,  neuromuscular  blockers;  CVP,  central
venous pressure;  F-R,  ﬂuid  responsiveness;  MAP,  mean  arterial  blood  pressure;  LacCl,  blood  lactate  clearance;  ScvO2,  central  venous
oxygen saturation;  PP,  pulse  pressure  variation;  ECHO,  hemodynamic  echocardiography;  dIVC,  distensibility  index  of  the  inferior
vena cava;  PLR,  passive  leg  raising;  RBC,  packed  red  blood  cells;  HCT,  hematocrit;  *,  for  patients  under  mechanical  ventilation;,
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ﬁorepinephrine  is  the  ﬁrst  choice  vasopressor  (see  text).
eﬂected  in  the  wide  range  of  MAP  goals  adopted  in  stud-
es  involving  septic  patients.29 The  rationale  supporting  the
nclusion  of  arterial  blood  pressure  in  the  septic  shock  resus-
itation  algorithm  is  based  on  the  principle  of  blood  ﬂow
utoregulation  (Fig.  3).  Accordingly,  if  cardiac  output  is
aintained  constant,  blood  ﬂow  to  tissues  does  not  change
ntil  the  blood  pressure  falls  below  a  critical  value.  When
his  critical  value  is  approached,  any  additional  reduction
n  arterial  pressure  will  impair  tissue  blood  ﬂow.  Since  dif-
erent  organs  have  distinct  critical  thresholds,  the  optimal
rterial  blood  pressure  to  be  achieved  remains  undeter-
ined.
Small  prospective  studies  addressed  the  effects  of  differ-
nt  MAP  levels  in  septic  shock  patients.  Increasing  MAP  from
5  to  85  mmHg  did  not  improve  systemic  oxygen  consump-
ion,  skin  microcirculatory  blood  ﬂow,  splanchnic  perfusion
b
t
w
ir  renal  function,  and  was  associated  with  a  higher  left
entricular  stroke  work  index  and  increased  exposure  to
atecholamines.24,25 Additionally,  although  increasing  MAP
rom  60  to  90  mmHg26 or  from  65  to  85  mmHg27,28 with
orepinephrine  improved  systemic  oxygen  delivery  and  the
utaneous  tissue  partial  pressure  of  oxygen,  contradictory
ndings  on  sublingual  microcirculation  were  reported.26--28
The  impact  of  two  MAP  targets  (65--70  mmHg  and
0--85  mmHg)  on  28  day  mortality  was  recently  evaluated
n  776  septic  shock  patients.6 Although  the  28  day  mortality
id  not  differ  between  the  groups,  the  incidence  of  atrial
brillation  was  higher  in  patients  randomized  to  the  high
lood  pressure  group  in  comparison  to  patients  allocated
o  low  MAP  group.6 Taking  the  available  evidence  together,
e  conclude  that  targeting  higher  MAP  levels  during  the
nitial  resuscitation  of  septic  shock  increases  the  exposure
Hemodynamic  support  in  septic  shock  
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Figure  3  Auto  regulation  of  blood  ﬂow  to  the  tissues  driven  by
the perfusion  pressure  curve.  In  situations  of  severe  hypotension
(mean  arterial  pressure  <50  mmHg),  blood  ﬂow  to  the  tissues  is
decreased,  leading  to  hypoxia.  On  the  other  hand,  during  severe
hypertension  (mean  arterial  pressure  >150  mmHg),  there  is  an
increase  in  blood  ﬂow  to  the  tissues  that  can  result  in  leakage  of
blood  components  into  the  interstitial  space.  In  both  situations,
when the  auto  regulatory  threshold  is  reached,  auto  regulation
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represents  the  perfusion  pressure.
to  ﬂuids,  vasopressors  and  inotropes,  which  has  been  asso-
ciated  with  increased  incidence  of  side  effects,  morbidity
and  mortality.30 Nevertheless,  targeting  lower  MAP  levels
may  increase  the  incidence  of  tissue  hypoperfusion  and  con-
tribute  to  the  progression  of  organ  dysfunction.31,32
Mixed  venous  and  central  venous  oxygen  saturation
In  conditions  under  reduced  oxygen  delivery,  the  oxy-
gen  consumption  can  be  satisﬁed  if  the  tissue  oxygen
extraction  increases  proportionally.  If  the  oxygen  delivery
reduction  persists,  anaerobic  metabolism,  lactic  acidosis
and  organ  dysfunction  may  develop  (Fig.  1).33 The  mixed
venous  oxygen  saturation  is  measured  in  the  blood  col-
lected  through  a  pulmonary  artery  catheter  and  its  value
provides  information  regarding  to  the  systemic  oxygen  con-
sumption.
The  mixed  venous  oxygen  saturation  values  are  not  equal
to  the  central  venous  oxygen  saturation,  which  represents
the  oxygen  saturation  measured  in  the  blood  collected  from
the  superior  vena  cava  at  the  entrance  to  the  right  atrium.34
Although  the  differences  between  ScvO2  and  SvO2  values
can  vary  across  different  clinical  conditions,  the  overall
trends  of  both  measurements  are  similar.35
Assuming  arterial  oxygen  saturation  of  100%,  the  oxygen
extraction  rate  (O2ER)  can  be  summarized  by  ‘‘1  --  SvO2’’,
in  a  simpler  way  than  using  oxygen  consumption  and  delivery
calculations  to  guide  therapy  at  the  bedside.33 Nevertheless,
it  is  important  to  empathize  that  the  oxygen  extraction  rate
needs  to  be  analyzed  as  a  function  of  the  cardiac  output
and  in  association  with  other  perfusion  parameters.33 A  low
mixed  venous  oxygen  saturation  can  be  adequate  in  compen-
sated  chronic  heart  failure  patients  or  in  patients  recovering
from  shock  (ﬂow  redistribution),  and  may  be  high  and  ade-
quate  in  some  chronic  cirrhotic  patients.  Because  of  that,
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he  recommendations  to  reach  ScO2  ≥65%  or  a  ScvO2  ≥70%
epresent  a  simpliﬁcation,  only  valid  during  the  ﬁrst  6  h  of
eptic  shock  (Fig.  2).15
actate  clearance
he  lactate  is  an  intermediate  compound  of  the  glucose
etabolism,  produced  in  the  cytoplasm  from  pyruvate.
n  aerobic  conditions,  the  pyruvate  is  produced  via  gly-
olysis  and  is  metabolized  by  the  mitochondrial  aerobic
xidation  pathway  via  the  Krebs  cycle,  bypassing  the  pro-
uction  of  lactate.  In  anaerobic  conditions,  the  decreased
itochondrial  oxidative  phosphorylation  results  in  a  raised
ool  of  pyruvate.  This  excess  of  pyruvate  is  converted
nto  lactate.  Lactate  production  occurs  in  multiple  organs,
uch  as  muscle,  skin,  brain,  intestine  and  red  blood
ells  and  its  clearance  takes  ground  in  the  liver,  kid-
eys  and  heart.  Thus,  an  impaired  lactate  clearance  or
xcessive  lactate  production  can  result  in  high  blood  lac-
ate  levels.  The  normal  arterial  lactate  level  is  below
.0  mmol/L.36
In  most  shock  states,  particularly  those  presenting  with
ow  cardiac  output,  hyperlactatemia  reﬂects  end-organ  cel-
ular  dysoxia  due  to  tissue  hypoperfusion.  Indeed,  even
fter  normalizing  the  traditional  hemodynamic  parameters,
uch  as  CVP,  MAP,  cardiac  output  and  SvO2,  critically  ill
atients  may  still  have  ongoing  tissue  hypoxia  (i.e.  occult
ypoperfusion).37 Therefore,  lactate  has  been  used  as  a  sur-
ogate  marker  of  tissue  hypoperfusion  and  as  a  biomarker  for
orbidity  and  mortality  in  septic  shock  patients.  Both  inter-
ediate  (2.0--3.9  mmol/L)  and  high  (≥4.0  mmol/L)  serum
actate  levels  have  been  associated  with  increased  risk  of
eath.37
The  lactate  clearance  is  deﬁned  as  the  percentage  of
actate  cleared  over  a  period,  usually  2--6  h,  from  presenta-
ion  in  the  emergency  department  or  intensive  care  unit.38
or  each  10%  increase  in  lactate  clearance,  there  is  an  11%
ecrease  in  the  likelihood  of  death.38 A  lactate  clearance
ower  than  10%  from  its  baseline  value  is  an  independent
redictor  of  increased  in-hospital  mortality.38 In  a  multicen-
er,  open-label,  randomized  controlled  trial,  Jansen  et  al.
nrolled  patients  admitted  to  the  intensive  care  unit  with
actate  ≥3.0  mEq/L.39 In  one  group,  the  resuscitation  was
uided  by  the  clearance  of  lactate  (decrease  of  20%  or
ore  per  2  h  for  the  initial  8  h  in  intensive  care  unit).  The
ontrol  group  had  only  the  initial  lactate  measure  and  no
actate  guided  therapy.  The  patients  in  the  lactate-guided
reatment  group  had  lower  adjusted  in-hospital  mortality
hazard  ratio  0.61,  95%  CI  0.43--0.87;  p  =  0.006)  and  inten-
ive  care  unit  mortality  (hazard  ratio  0.66,  95%  CI  0.45--0.98;
 =  0.037).39
The  lactate  clearance  was  compared  to  central  venous
xygen  saturation  as  indicator  of  adequate  tissue  oxygen
elivery  during  the  initial  resuscitation  of  severe  sepsis  and
eptic  shock  patients  in  a  non-inferiority  trial.40 In  this  study,
argeting  a  lactate  clearance  of  at  least  10%  produces  a  sim-
lar  short-term  survival  rate  as  a  protocol  using  ScvO2.40hese  data  support  lactate  clearance  as  an  alternative  to
cvO2  monitoring,  with  the  advantage  of  not  requiring  a
entral  line  placement  and  its  associated  risks  and  costs
Fig.  2).
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he  correction  of  hypovolemia  and  tissue  hypoperfusion
hrough  ﬂuid  administration  aims  to  increase  tissue  oxygen
elivery  by  increasing  cardiac  output.  Currently,  the  ﬂuid  of
hoice  for  the  initial  resuscitation  of  septic  shock  patients
s  crystalloids,  at  an  initial  ﬂuid  challenge  of  30  mL/kg.15
ased  on  data  from  recently  published  trials,  hydroxyethyl
tarch  (HES)  should  not  be  used  for  ﬂuid  resuscitation.
Several  studies  and  meta-analyses  have  shown  the  dele-
erious  effects  of  HES  compared  to  crystalloids  for  septic
hock  resuscitation.41--45 Hydroxyethyl  starch  increases  the
isk  of  bleeding,  acute  renal  failure  and  the  need  for  renal
eplacement  therapy.44,45
The  VISEP  trial  assessed  the  safety  and  efﬁcacy  of  inten-
ive  insulin  therapy  against  conventional  therapy  and  10%
ES  200/0.5  against  Ringer’s  lactate  in  patients  with  severe
epsis  or  septic  shock.41 This  study  was  stopped  prematurely
ue  to  the  high  risk  of  hypoglycemia  in  the  intensive  insulin
herapy  group.  The  comparison  between  HES  200/0.5  and
inger’s  lactate  continued  with  all  patients  receiving  con-
entional  insulin  therapy.  The  trial  was  stopped  after  the
rst  interim  analysis,  because  of  increased  rate  of  renal  fail-
re  and  a  trend  toward  higher  mortality  at  90  days  in  the  HES
roup.41
The  6S  trial  enrolled  severe  sepsis  patients  to  ﬂuid  resus-
itation  with  either  6%  HES  130/0.42  or  Ringer’s  acetate.42
n  this  study,  HES  130/0.42  signiﬁcantly  increased  the  risk
f  death  (51%  vs.  43%;  p  =  0.03)  or  dependence  on  dialysis
t  90  days  (22%  vs.  16%;  p  =  0.04).  The  CHEST  trial  randomly
ssigned  7000  critically  ill  patients  to  receive  6%  HES  130/0.4
n  0.9%  saline  or  0.9%  saline  alone  for  ﬂuid  resuscitation.43
here  was  no  signiﬁcant  difference  in  90  day  mortality
etween  the  two  groups.  Nevertheless,  more  patients  who
eceived  HES  130/0.4  needed  renal  replacement  therapy.43
he  CRISTAL  trial  compared  colloids  (gelatins,  dextrans,  HES
r  albumin  4%  or  20%)  vs.  crystalloids  (isotonic/hypertonic
aline  or  Ringer  lactate)  in  hypovolemic  shock  resuscitation
including  sepsis,  trauma  and  no-trauma  no-sepsis).  There
as  no  difference  between  groups  in  28  day  mortality  (rel-
tive  risk  0.96,  95%  CI  0.88--1.04;  p  =  0.26).46
Administration  of  albumin  should  be  considered  in
atients  requiring  substantial  amounts  of  crystalloids. 15 The
argest  trial  to  date  that  compared  hypooncotic  albumin
4%  solution)  with  normal  saline  in  a  general  critically  ill
opulation  was  the  SAFE  trial.47 This  study  showed  no  dif-
erence  28  day  mortality  between  the  groups.  A  subgroup
nalysis  including  only  severe  sepsis  patients  demonstrated
hat  albumin  administration  was  independently  associated
ith  mortality  reduction  (odds  ratio  0.71,  95%  CI:  0.52--0.97;
 =  0.03).48 Nevertheless,  this  ﬁnding  was  not  conﬁrmed  in
he  most  recent  trial  in  which  1818  severe  sepsis  and  sep-
ic  shock  patients  were  randomized  to  receive  either  20%
lbumin  and  crystalloid  solution  or  crystalloid  solution  alone
uring  ICU  stay.7asopressors
ystemic  vasodilatation  and  arterial  hypotension  are  land-
arks  of  severe  sepsis  and  septic  shock.  When  adequate
v
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uid  resuscitation  is  not  enough  to  restore  the  arterial  blood
ressure,  vasopressor  administration  should  be  initiated
Fig.  2).15 A  meta-analysis  including  six  randomized  clinical
ith  1408  patients  compared  norepinephrine  vs.  dopamine
s  ﬁrst-line  vasopressors  in  septic  shock.49 Dopamine  admin-
stration  was  associated  with  a  higher  risk  of  death  (relative
isk  1.12,  95%  CI  1.01--1.20;  p  =  0.035)  and  a  higher  risk  of
ardiac  arrhythmias  (relative  risk  2.34,  95%  CI  1.46--3.77;
 = 0.001).  Based  on  these  ﬁndings,  norepinephrine  has  been
ecommended  as  the  vasopressor  of  choice  in  septic  shock
atients  (Fig.  2).15 Alternative  vasopressors  include  low
oses  of  vasopressin,  epinephrine  (added  or  potentially  sub-
tituted  for  norepinephrine)  and  dopamine  in  highly  selected
atients  (low-risk  for  arrhythmia).15
Vasopressin,  also  known  as  antidiuretic  hormone,  is  syn-
hesized  in  the  paraventricular  and  supraoptic  nuclei  of
he  hypothalamus  and  released  into  the  systemic  circu-
ation  from  the  posterior  pituitary  gland  in  response  to
ecreased  intravascular  volume  and  increased  plasma  osmo-
ality.  The  vasoconstrictive  effect  of  vasopressin  on  vascular
mooth  muscle  is  mediated  by  V1  receptors.  It  is  one  of
he  most  important  stress-related  hormones  and  a  rela-
ive  vasopressin  deﬁciency  may  develop  during  septic  shock
rogression.50
Low  doses  of  vasopressin  may  be  added  to  norepinephrine
o  maintain  arterial  blood  pressure  in  refractory  septic  shock
nd  to  decrease  exposure  to  norepinephrine.15 The  VASST
rial  compared  the  administration  of  low  doses  of  vaso-
ressin  (0.01--0.03  U/min)  vs.  norepinephrine  in  septic  shock
atients.51 The  authors  reported  no  signiﬁcant  differences
etween  the  two  respective  groups  regarding  28  day  mortal-
ty  (35.4%  vs.  39.3%;  p  =  0.26),  90  day  mortality  (43.9%  vs.
9.6%;  p  =  0.11)  or  the  rate  of  serious  adverse  events.51 The
ain  concern  about  vasopressin  administration  is  related
o  decreased  blood  ﬂow  to  the  heart,  intestine  and  limbs,
specially  when  higher  doses  are  used.50
Epinephrine  is  a  potent  -  and  -adrenergic  cate-
holamine  that  increases  MAP  by  increasing  both  cardiac
utput  and  systemic  vascular  resistance.  Epinephrine
dministration  may  also  transiently  increase  the  lactate
oncentration,  probably  due  to  increased  aerobic  glycolysis
hrough  Na+K+ ATPase  stimulation  within  the  skeletal  mus-
les  rather  than  through  tissue  dysoxia.52 Epinephrine  alone
as  compared  to  norepinephrine  associated  with  dobut-
mine  administration  in  a  prospective  multicenter  study,
hich  included  330  septic  shock  patients.52 The  28  and
0  day  mortality  rates,  time  to  hemodynamic  stabilization,
umber  of  vasopressor-free  days  and  rate  of  serious  adverse
ffects  did  not  differ  between  the  study  groups.  Never-
heless,  a  transient  increase  in  the  lactate  concentration
as  observed  between  days  1  and  4  in  the  epinephrine
roup.52
notropes  and  blood  transfusion
obutamine,  a  1-agonist  catecholamine,  is  recommended
n  the  presence  of  myocardial  dysfunction,  suggested  by  ele-
ated  cardiac  ﬁlling  pressures  and  low  cardiac  output  or
n  the  presence  of  signs  of  hypoperfusion  despite  adequate
ntravascular  volume  replenishment  and  achievement  of  an
AP  higher  than  65  mmHg  (Fig.  2).15
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2Hemodynamic  support  in  septic  shock  
Finally,  the  Surviving  Sepsis  Campaign  Guidelines  rec-
ommend  red  blood  cell  transfusion  aiming  to  reach  an
hematocrit  of  at  least  30%  (Fig.  2).15 Nevertheless,  there
is  no  strong  evidence  that  higher  hemoglobin  targets
(>9.0  g/dL)  are  beneﬁcial  in  the  absence  of  coronary  heart
disease  or  stroke,  and  several  concerns  exist  regarding
higher  oxygen  afﬁnity  of  stored  hemoglobin.53,54 The
recently  published  TRISS  trial  was  a  randomized  controlled
study  that  compared  two  different  hemoglobin  transfusion
thresholds  (≤7.0  g/dL  and  ≤9.0  g/dL)  in  almost  a  thousand
septic  shock  patients.10 The  authors  reported  no  signiﬁcant
90  day  mortality  difference  between  the  groups  (relative  risk
0.94,  95%  CI  0.78--1.09,  p  =  0.44),  although  the  lower  thresh-
old  group  received  half  of  a  red  blood  cell  transfusion  when
compared  to  the  higher  threshold.  Additionally,  there  was
no  difference  in  the  incidence  of  cardiac  and  non-cardiac
ischemic  events.10
Conclusion
Prompt  and  aggressive  treatment  of  septic  shock  patients
improves  morbidity  and  mortality.  Early  recognition  in
addition  to  ﬂuid  resuscitation  and  proper  antibiotics  admin-
istration  to  patients  are  the  cornerstone  of  the  treatment.
Along  with  it,  a  comprehensive  clinical  bedside  evaluation
and  an  accurate  assessment  of  ﬂuid  responsiveness  seem
to  be  the  best  available  evidence-based  medicine  for  sep-
tic  shock  resuscitation.  In  the  light  of  the  new  ﬁndings
presented  in  recently  published  trials,  a  review  of  the  goal-
directed  therapy,  as  it  was  conceived,  is  necessary.
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